Rising rates of diabetes and obesity have been recognized as a single new epidemic called "diabesity." The challenge now is for healthcare professionals to treat obesity and diabetes as part of the same condition instead of separating them into two unlinked conditions.

At the forefront of cardiology, the Cardiac Arrhythmia team at the Freeman Hospital in Newcastle have been trialing OMRON's handheld ECG monitor, HeartScan, as a more comprehensive way of monitoring patients in the year following catheter ablation of atrial fibrillation.

Healthcare guidance body NICE has published draft recommendations on the diagnosis and management of lower limb peripheral arterial disease (PAD).

NHS Trusts should double their efforts to offer cardiac rehabilitation services to patients to reduce "the shocking inequalities in treatment after a heart attack in England", finds a report from Heart UK.

The release of the updated NICE Guideline for the Clinical Management of Primary Hypertension in Adults, in August 2011, brought significantly increased awareness to the importance for GPs to use ambulatory blood pressure monitors to observe patients for hypertension.

A new pooled analysis presented today at the International Diabetes Federation (IDF) 21st World Diabetes Congress has demonstrated that people with type 2 diabetes taking 'Januvia' (sitagliptin) experienced a lower incidence of major cardiovascular (CV) events (MACE)* compared to those treated with a sulphonylurea (SU).¹

Diabetics who experience low blood sugar attacks while driving are the focus of a new health campaign launched by TREND, a diabetes nursing group together with the Automobile Association (AA) and MSD Diabetes.

Sevikar HCT®▼ simplifies treatment and could improve the management of hypertension

Panasonic have announced the European availability of its innovative ultrasound tool for personalized preventive medicine, the CardioHealth Station.

NICE has today (Wednesday 9 November) opened a consultation on new draft guidance on identifying people at high risk of developing type 2 diabetes and the provision of clinically and cost effective interventions to help reduce the risk or delay the onset of the condition.